The activity of class I, II, III, and IV alcohol dehyrogenase isoenzymes and aldehyde dehydrogenase in endometrial cancer

Orywal, Karolina; Jelski, Wojciech; Zdrodowski, Michał; Szmitkowski, Maciej

doi:10.1002/jcla.20412

Cited by 10 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the serum and tissue expression level of class I and total ADH were significantly increased in liver,27,28 colorectal,29,30 and brain cancers,31,32 while ALDH levels were not statistically significant different between cancer patients and healthy subjects. The upregulation trend of class I ADH between cancer and healthy tissue can also be found in cervical,33 ovarian,34 endometrial,35 and renal cell cancers,36 whereas the upregulation trend of class I ADH for cancer serum has been reported in bladder and esophageal cancers 37,38. However, the expression of class I ADH in breast cancer was significantly decreased compared to the tissue of healthy subjects, and the expression of ALDH was unchanged 39.…”

Section: Discussionmentioning

confidence: 94%

Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma

Liao¹,

Huang²,

Liu³

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundAlcohol dehydrogenase (ADH) isoenzymes have been reported as a potential diagnostic marker for pancreatic cancer, but their prognostic value in pancreatic cancer remains unclear. The aim of this investigation was to identify the prognostic value of ADH genes in human patients with pancreatic adenocarcinoma (PAAD).Materials and methodsAn RNA sequencing dataset and corresponding survival profiles of PAAD were obtained from The Cancer Genome Atlas. Survival analysis and gene set enrichment analysis were used to investigate the prediction value and potential mechanism of ADH genes in PAAD prognosis.ResultsSurvival analysis of ADH genes suggests that a high expression of ADH1A (adjusted P=0.037, adjusted hazard ratio [HR] =0.627, 95% CI =0.404–0.972) and ADH6 (adjusted P=0.018, adjusted HR =0.588, 95% CI =0.378–0.914) were associated with a significantly decreased risk of death, while a high expression of ADH5 was associated with a significantly increased risk of death (adjusted P=0.043, adjusted HR =1.564, 95% CI =1.013–2.414). Joint effects analysis of three ADH gene prognostic markers suggests that the prognosis difference for any marker combination was more significant than that for any individual marker. The potential mechanism of ADH1A and ADH6 in PAAD prognosis was that a high expression of ADH1A and ADH6 was involved in the P450 pathway and biological processes, while high ADH5 expression was involved in transforming growth factor β regulation-related pathways and biological processes, Wnt, the cell cycle, ErbB, and mitogen-activated protein kinase signaling pathways.ConclusionOur data suggest that ADH1A, ADH5, and ADH6 expression may be potential prognostic markers of PAAD and in combination have a strong interaction and better predictive value for PAAD prognosis.

show abstract

Section: Discussionmentioning

confidence: 94%

Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma

Liao¹,

Huang²,

Liu³

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…Similarly, as in the serum results of patients with malignant neoplasms, ADH isoenzyme activity has been identified in tumor tissues ( 37 ). Studies have additionally reported that class I ADH isoenzymes are significantly increased in the tumor tissue of cervical cancer ( 47 ), ovarian cancer ( 48 ), endometrial cancer ( 49 ), brain cancer ( 50 ), liver cancer ( 44 , 51 ), CRC ( 52 , 53 ) and renal cell carcinoma ( 54 ) compared with healthy tissue, whereas ALDH isoenzymes in these cancer types did not demonstrate a statistically significant difference between cancer and healthy tissue. However, a downregulation of class I ADH was observed in breast cancer tissues ( 55 ), whereas the expression of other ADH isoenzymes remained unchanged.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of alcohol dehydrogenase mRNA expression in gastric cancer

et al. 2018

View full text Add to dashboard Cite

Previous studies have reported that alcohol dehydrogenase (ADH) isoenzymes possess diagnostic value in gastric cancer (GC). However, the prognostic value of ADH isoenzymes in GC remains unclear. The aim of the present study was to identify the prognostic value of ADH genes in patients with GC. The prognostic value of ADH genes was investigated in patients with GC using the Kaplan-Meier plotter tool. Kaplan-Meier plots were used to assess the difference between groups of patients with GC with different prognoses. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the relative risk of GC survival. Overall, 593 patients with GC and 7 ADH genes were included in the survival analysis. High expression of ADH 1A (class 1), α polypeptide (ADH1A; log-rank P=0.043; HR=0.79; 95% CI: 0.64–0.99), ADH 1B (class 1), β polypeptide (ADH1B; log-rank P=1.9×10−05; HR=0.65; 95% CI: 0.53–0.79) and ADH 5 (class III), χ polypeptide (ADH5; log-rank P=0.0011; HR=0.73; 95% CI: 0.6–0.88) resulted in a significantly decreased risk of mortality in all patients with GC compared with patients with low expression of those genes. Furthermore, protective effects may additionally be observed in patients with intestinal-type GC with high expression of ADH1B (log-rank P=0.031; HR=0.64; 95% CI: 0.43–0.96) and patients with diffuse-type GC with high expression of ADH1A (log-rank P=0.014; HR=0.51; 95% CI: 0.3–0.88), ADH1B (log-rank P=0.04; HR=0.53; 95% CI: 0.29–0.98), ADH 4 (class II), π polypeptide (log-rank P=0.033; HR=0.58; 95% CI: 0.35–0.96) and ADH 6 (class V) (log-rank P=0.037; HR=0.59; 95% CI: 0.35–0.97) resulting in a significantly decreased risk of mortality compared with patients with low expression of those genes. In contrast, patients with diffuse-type GC with high expression of ADH5 (log-rank P=0.044; HR=1.66; 95% CI: 1.01–2.74) were significantly correlated with a poor prognosis. The results of the present study suggest that ADH1A and ADH1B may be potential prognostic biomarkers of GC, whereas the prognostic value of other ADH genes requires further investigation.

show abstract

“…The study of ADH activity in women with uterus cancer are consistent with ovarian cancer results. In endometrial cancer and cervical cancer cells was found higher activity of ADH I and the total ADH without any changes in ALDH activity [6,7]. The study in women with breast cancer has shown an inverse association.…”

Section: Discussionmentioning

confidence: 83%

“…Acetaldehyde is the first metabolite of alcohol oxidation, mediated by alcohol dehydrogenase (ADH). Recent data shows that healthy and also cancerous cells of endometrium and cervix contain ADH class I, III and IV isoenzymes [6,7].…”

Section: Introductionmentioning

confidence: 99%

The activity of class I, II, III and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in ovarian cancer and ovarian cysts

Orywal

Jelski

Zdrodowski

et al. 2013

Advances in Medical Sciences

View full text Add to dashboard Cite

The activity of class I, II, III, and IV alcohol dehyrogenase isoenzymes and aldehyde dehydrogenase in endometrial cancer

Abstract: The increased activity of total ADH in endometrial cancer, especially the class I isoenzyme and normal activity of ALDH, may be the cause of disorders in metabolic pathways that use these isoenzymes and could increase the concentration of acetaldehyde, which is cancerogenic substance.

Cited by 10 publications

References 30 publications

Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma

Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma

Prognostic value of alcohol dehydrogenase mRNA expression in gastric cancer

The activity of class I, II, III and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in ovarian cancer and ovarian cysts

Contact Info

Product

Resources

About